<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780386</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1805_BE</org_study_id>
    <nct_id>NCT04780386</nct_id>
  </id_info>
  <brief_title>Compare the Pharmacokinetics of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2</brief_title>
  <acronym>NVP-1805</acronym>
  <official_title>A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics of NVP-1805 and coadministration&#xD;
      of NVP-1805-R1 with NVP-1805-R2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      pharmacokinetics and safety of NVP-1805 compared to coadministration of NVP-1805-R1 with&#xD;
      NVP-1805-R2&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2020</start_date>
  <completion_date type="Actual">February 16, 2021</completion_date>
  <primary_completion_date type="Actual">November 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: AUClast</measure>
    <time_frame>0hours - 72hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: Cmax</measure>
    <time_frame>0hours - 72hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NVP-1805</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-1805</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1805-R1 and NVP-1805-R2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>coadministration of NVP-1805-R1 and NVP-1805-R2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1805</intervention_name>
    <description>orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)</description>
    <arm_group_label>NVP-1805</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1805-R1and NVP-1805-R2</intervention_name>
    <description>orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)</description>
    <arm_group_label>NVP-1805-R1 and NVP-1805-R2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult subjects who signed informed consent&#xD;
&#xD;
          -  BMI of &gt;18.0 kg/㎡ and &lt;30.0 kg/㎡ subject, weight more than 50kg(45 kg or more for&#xD;
             woman)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects participated in another clinical trial within 6 months prior to&#xD;
             administration of the study drug&#xD;
&#xD;
          -  Inadequate subject for the clinical trial by the investigator's decision&#xD;
&#xD;
          -  Subjects participated in another clinical trial within 6 months prior to&#xD;
             administration of the study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaewoo Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H Plus Yangji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H Plus Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Nambusunhwan-ro</state>
        <zip>08779</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

